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Increased aggregation of Aβ occurs in the brain of all patients with 
Alzheimer's disease (AD) and is considered an important step in the 
disease pathogenesis. There is substantial evidence that certain 
components of the low-density lipoprotein (LDL) receptor family 
and their ligands are involved in Aβ aggregation and/or clearance 
(Cam, Zerbinatti, Li, & Bu, 2005; Kanekiyo & Bu, 2014; Lane-
Donovan, Philips, & Herz, 2014; Sagare, Deane, & Zlokovic, 2012; 
Ulery et al., 2000; Zlokovic, Deane, Sagare, Bell, & Winkler, 2010). 
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m|uo71|bomĹOne of the major neuropathological features of Alzheimer's disease 
(AD) is the accumulation of amyloid-β (Aβ) protein in the brain. Evidence suggests 
that the low-density lipoprotein receptor-associated protein (RAP) binds strongly to 
Aβ and enhances its cellular uptake and that decreased RAP expression correlates 
with increased Aβ production in animal models of AD.
;|_o7vĹThe current study examined whether RAP levels change in AD human brain 
tissue and whether they are related to the amount of AD pathology. RAP and NeuN 
levels were determined by Western blot, while low-density lipoprotein receptor-re-
lated protein 1 (LRP1), tau and Aβ levels were determined by ELISA in the temporal 
cortex of 17 AD and 16 control cases.
!;vѴ|vĹAn increase in total Aβ and insoluble and soluble tau protein was observed in 
AD brain tissue. In contrast, RAP levels were significantly decreased in AD brain tis-
sue compared to controls. Correlation analysis revealed that levels of RAP correlated 
with both total Aβ and soluble and insoluble tau levels. Neither LRP1 nor NeuN levels 
were significantly altered in AD brain tissue homogenates and did not correlate with 
Aβ or tau protein levels.
om1ѴvbomĹReduction in RAP may contribute to the accumulation and aggregation 
of Aβ in the AD brain.
  + ) !	 "
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In particular, the low-density lipoprotein receptor-related protein 
1 (LRP1) plays an important role in Aβ degradation and transport 
across the blood–brain barrier (Kanekiyo et al., 2011, 2013; Liu 
;|-ѴĺķƑƏƐƕĸ-;|-ѴĺķƑƏƐѶĸ"_b0-|-;|-ѴĺķƑƏƏƏĸ"|ou1h;|-ѴĺķƑƏƐѵőķ
although its ability to bind Aβ directly has been questioned (Yamada 
et al., 2008) and studies assessing AD brain tissue levels have 
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the receptor-associated protein (RAP), is capable of binding to Aβ 
and inhibiting its aggregation and toxicity (Kerr et al., 2010) as well 
as enhancing its cellular uptake (Kanekiyo & Bu, 2009), thereby 
playing a potentially important role in Aβ aggregation (Van Uden 
et al., 2002; Xu et al., 2008). Indeed, RAP deficiency increases Aβ 
deposition in murine transgenic models of AD (Xu et al., 2008) and 
reduces Aβ clearance (Van Uden et al., 2002), and a previous im-
munohistochemical study has demonstrated decreased RAP immu-
nohistochemistry in AD brain tissue (John Provias & Jeynes, 2010). 
The aim of the present study was to quantify protein levels of RAP 
in AD brain tissue and determine the relationship between RAP 
and major AD pathologies (Aβ and tau) and cell loss (NeuN). Our 
data demonstrate a significant decrease in RAP but not LRP1 in 
AD brain tissue. RAP, but not LRP1, levels were inversely associ-
ated with increases in Aβ and tau protein levels but no association 
with NeuN was identified. This strong association between RAP 
and AD pathologies lends further weight to a role for RAP in AD 
pathogenesis.
ƑՊ |Պ$	"
ƑĺƐՊ|Պ-v;1_-u-1|;ub-|bom-m7|bvv;v
Fresh-frozen brain tissue from the inferior temporal cortex was 
provided from the Sydney Brain Bank for 33 cases, including 17 AD 
and 16 pathological and disease-free controls, (Table 1). Consent 
for serial standardized assessments and autopsy, and the use of tis-
sue for research purposes were obtained for all cases, and the brain 
donor program and tissue banking were approved by the Human 
Research Ethics Committee of the University of New South Wales. 
Neuropathology was confirmed using systematic assessments, as 
ru;bovѴ7;v1ub0;7 Ő"_;r_;u7ķ1-mmķ$_b;Ѵķş-ѴѴb7-ķƑƏƏƑőĺ
Cases with head injury, significant cerebrovascular disease including 
stroke, and nontau intracellular inclusions or substantive neurode-
generation in the absence of intracellular inclusions were excluded. 
Alzheimer's disease cases met criteria for a high likelihood of AD 
Őom|bm; ;| -Ѵĺķ ƑƏƐƑőĺ 	bv;-v;Ŋ=u;; 1om|uoѴv ;u; 1-v;v b|_o|
neurological or neuropsychiatric disorders and without significant 
neuropathology.
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Crude protein extracts were prepared from 200 mg of frozen 
human brain tissue taken from the inferior temporal cortex for 
analysis of Aβ (Tris-buffered saline (TBS) soluble, sodium dodecyl 
sulfate (SDS) soluble and formic acid soluble), NeuN (SDS soluble), 
RAP (SDS soluble), and LRP1 (SDS soluble). Our preliminary stud-
ies showed that NeuN, RAP, and LRP1 were located in the SDS 
fraction, so protein levels were analyzed in these fractions. Tissue 
-v =buv| _olo];mb;7 bm $ubv 0==;u ŐƑƏl $ubvŊѴķ ƐƑƔl
-Ѵķ Ɣl 	$ķ ƏĺƏƑѷ vo7bl -b7;ő 1om|-bmbm] ruo|;-v; bm-
hibitors (Roche), followed by centrifugation at 120,000 g for 2 hr 
at 4°C, with supernatant collected as the TBS-soluble tissue frac-
|bomĺ$_;r;ѴѴ;|-vu;vvr;m7;7bm$"0==;u1om|-bmbm]Ƒѷ"	"
and centrifuged at 120,000 g for 30 minutes at 25°C. The result-
ing membrane-associated supernatant was retained as the SDS-
voѴ0Ѵ; =u-1|bomĺ $_; u;l-bmbm] r;ѴѴ;| -v u;vvr;m7;7 bm ƕƏѷ
formic acid (v/v) and centrifuged at 120,000 g for 1 hr at 4°C. The 
supernatant containing the insoluble proteins was retained as the 
insoluble fraction.
Tau was extracted as previously described (van Eersel 
et al., 2009). Briefly, tissue was homogenized in reassembly buf-
=;uŐ!őŐƏĺƕƔ-ѴķƐƏƏmƑŊŐŊlour_oѴbmoő;|_-m;vѴ=omb1
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containing protease inhibitors, Roche). Homogenates were in-
cubated on ice for 20 minutes while shaking and centrifuged at 
100,000 g for 1 hr at 4°C. The resulting supernatant was retained 
as the RAB-soluble protein fraction. The pellet was resuspended 
bmr-bu;7_;Ѵb1-Ѵ=u-1|bomŐ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15,000 g for 20 minutes at 4°C. The supernatant was retained, and 
the pellet re-extracted in PHF extraction buffer and centrifuged 
at 15,000 g for 20 minutes at 4°C. The supernatants were pooled 
-m7|u;-|;7b|_Ɛѷv-uhovѴ=ouƐ_u-|ƑƔŦrubou|o1;m|ub=]--
tion at 100,000 g for 30 minutes. The pellet was resuspended in 
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sarkosyl-insoluble protein fraction.
The protein concentrations of all fractions were measured using 
a bicinchoninic acid assay (Pierce BCA Protein Assay Kit, Thermo 
Scientific), according to the manufacturer's instructions. Samples 
;u;v|ou;7-|ƴѶƏŦm|bѴv;ĺ
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Semiquantitative analysis of NeuN and RAP was determined by 
Western blot analysis. 25 μg of protein lysate was heated with sam-
rѴ;0==;uŐƑѷ"	"ķƑƏѷ]Ѵ1;uoѴķƑĺƔѷ0uolor_;moѴ0Ѵ;ķƐƑĺƔl
$ ƐՊGroup demographics for cohorts
om|uoѴ 	
Age at death (years) 74 ± 8 78 ± 10
Postmortem interval (hrs) 31 ± 17 27 ± 24
Disease duration (years) - 7 ± 3
Note: Group values are expressed as mean ± standard deviation.
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SDS-PAGE gels before transfer to nitrocellulose membranes (Bio-
Rad). Antigen retrieval was performed on the NeuN membranes by 
0obѴbm] bmƐ" ŐƏĺѶѷ-ѴķƐƏĺƐl-2HPO4·2H2ķƑĺѵѶl
ѴķƐĺƕѵl2PO4, pH 7.4) for 1 minute on each side, and for the 
other membranes by boiling in 1x citrate buffer (Fronine) pH 6.0, for 
3 minutes.
;l0u-m;v;u;0Ѵo1h;7 bmƔѷvhbllbѴhķ-v_;7 bmƐ$"Ŋ$
ŐƏĺѶƕѷ-Ѵķ ƏĺƏƐ$ubvķ rƕĺƓķb|_ƏĺƐѷ$;;mŊƑƏőķ -m7 |_;m
incubated overnight in primary antibodies, which were mouse 
lomo1Ѵom-Ѵ -m|bŊ; ŐbѴѴbrou; ƒƕƕķ ƐĹƔķƏƏƏ 7bѴ|bomő -m7
mouse monoclonal anti-LRPAP1 (Abcam ab20368, 1:6,000 dilution) 
with rabbit polyclonal GAPDH (Sigma-Aldrich G9545, 1:4,000 dilu-
tion) used as a protein loading control. Protein detection was then 
performed using horseradish peroxidase-conjugated secondary 
antibodies for mouse (Bio-Rad #1,706,516) with enhanced chemi-
luminescence (Amersham ECL Plus Western Blot Detection System, 
GE Healthcare) or Alexa Fluor-conjugated secondary antibodies for 
rabbit (Sigma-Aldrich G9515).
boŊ!-7_;lb	o1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and the relative levels of each protein of interest were analyzed using 
Image Lab software (Life Science Research, Bio-Rad). The intensity 
of each protein band was quantified and expressed as arbitrary units 
standardized to GAPDH.
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Analysis of Aβ was carried out using a Novex ABeta 42 and ABeta 40 
Human ELISA kits (Life Technologies, Australia, VIC; cat # KHB3441 
and KHB3481) according to the manufacturer's instructions. Soluble 
and insoluble tau proteins were analyzed using the Novex TAU 
(pS396) Human ELISA Kit (Life Technologies, Australia, VIC; cat # 
ƕƏƒƐőĺ!Ɛ-m-Ѵvbv-v1-uub;7o|vbm]-bovou1;ѴoŊ
density lipoprotein receptor-related protein 1 (LDL-RP) ELISA kit 
Ő!;voѴbm] l-];vķ(ķv|u-Ѵb-ĸ 1-|Ų"ƕƑƕƏƐƐő -11ou7bm] |o
the manufacturer's instructions.
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All statistical analyses were performed using SPSS software (ver-
vbomƑƐ =ou-1ķ """ m1ĺőĺlѴ|bѴ;;Ѵlb;7lo7;Ѵb|_!ķ
LRP, NeuN, Aβ, and tau as the dependent variables was used to 
determine differences between control and AD groups. Age and 
postmortem delay were included as covariates. No significant ef-
fects of age (p > .08) or postmortem delay (p > .07) were iden-
tified so these variables were not considered further. Pearson's 
correlations were performed to determine relationships between 
variables. Aβ fractions were summed and analyzed as total Aβ 
(see Tables S1 and S2 for breakdown of fractional Aβ40 and Aβ42 
levels, respectively). Probability (p) values <.05 were considered 
statistically significant.
ƒՊ |Պ!"&$"
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Alzheimer's disease cases had significantly lower RAP levels com-
pared to controls (p < .0001, Figure 1a) although no significant dif-
ferences in the brain tissue levels of LRP1 (p = .45, Figure 1c) or NeuN 
(p = .59, Figure 1b) were seen between groups (Figure 1, Table 2).
ƒĺƑՊ|Պ!;Ѵ-|bomv_brv0;|;;m0u-bmruo|;bmѴ;;Ѵv
Consistent with neuropathological diagnosis, all AD cases had signif-
icantly greater Aβ and tau pathology compared to elderly controls. 
 &! ƐՊBar graphs showing RAP (a), NeuN (b), and LRP1 (c) 
protein levels in AD and control brain tissue. RAP protein levels 
were significantly reduced in AD temporal cortex compared to 
controls (*p < .0001). No significant difference in LRP1 and NeuN 
protein levels was observed between groups. Error bars = standard 
error
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In particular, the levels of total Aβ (p < .0001, Figure 2a), soluble tau 
(p < .0001, Figure 2b), and insoluble tau (p < .0001, Figure 2c) were 
significantly higher in AD cases (Figure 2, Table 2).
As expected, Pearson's correlation analysis revealed signifi-
cant positive associations between Aβ and both insoluble (R = .407, 
p = .028) and soluble (R = .775, p < .001) tau protein levels (data not 
shown).
Levels of RAP correlated negatively with total Aβ (R Ʒ ƴĺƓƑѵķ
p = .021, Figure 3a), soluble tau (RƷƴĺƔѶƑķp = .001, Figure 3b), and 
insoluble tau (RƷƴĺƔѵѵķp = .002, Figure 3c), In contrast, LRP1 levels 
did not show any relationship with total Aβ or tau (p > .05).
ƓՊ |Պ	"&""
Using biochemical methods, we show significantly reduced levels of 
RAP in AD brain tissue. Our data support a previous semiquantita-
tive immunohistochemical study showing a decrease in the neuronal 
distribution of RAP in AD (Provias & Jeynes, 2010). We further show 
that in AD, low RAP levels are associated with high Aβ and tau (solu-
ble and insoluble tau protein) pathologies, suggesting that RAP may 
play a role in the disease process and highlight the need for further 
research in this area.
As a chaperone protein, RAP is responsible for ensuring LRP1's 
effective transport to the cell surface (Bu & Schwartz, 1998) 
where it is known to play an important role in Aβ clearance (Sagare 
et al., 2012). RAP is also used as an effective LRP1 antagonist 
(Yamauchi et al., 2013), where it impacts cellular Aβ uptake (Yamada 
et al., 2008), indicating a mechanism whereby RAP can indirectly af-
fect Aβ. Conversely, down-regulation of RAP in AD transgenic mouse 
models has been shown to increase Aβ deposition (Xu et al., 2008), 
suggesting that this process is under tight homeostatic control. It 
has been widely speculated that increased Aβ deposition is primarily 
mediated by a decrease in the LDL receptor proteins, such as LRP1 
and SorLA, as a consequence of decreased RAP. However, our data 
demonstrate a significant negative association between Aβ and RAP 
but not between Aβ and LRP1 in AD brain tissue. Furthermore, the 
ability of RAP to bind Aβ and act independently of LRP1 is supported 
by previous animal studies showing RAP deficiency does not signifi-
cantly affect the levels of LRP1 (Xu et al., 2008), suggesting that ei-
ther a relatively modest change in LRP1 may be significant enough 
to cause changes in Aβ deposition or RAP possesses an ability to 
affect Aβ independently of LRP1 (Xu et al., 2008). The latter hypoth-
esis is supported by our previous studies demonstrating that RAP 
binds to Aβ and forms a complex (not necessarily colocalized with 
LRP1) on cell membranes (Kerr et al., 2010) and may be capable of 
enhancing the reuptake of Aβ in neuronal and glial cell cultures via 
an LRP1-independent mechanism (Kanekiyo & Bu, 2009). It has also 
been shown that extracellular RAP does not inhibit the degradation 
of Aβ by neurons (by utilizing its affinity for LRP1), further indicat-
ing an LRP1-independent mechanism of action (Narita, Holtzman, 
Schwartz, & Bu, 1997), which is not surprising given that many al-
ternative Aβ lipid-binding sites exist (Small et al., 2007; Subasinghe 
et al., 2003).
Despite a significant change in its chaperone protein, we did 
not identify a significant change in LRP1 in AD brain tissue or 
identify any association with Aβ or tau protein levels. This is not 
entirely surprising given previous studies have failed to report con-
sistent changes in LRP1 in AD brain tissue, with some showing no 
change (Causevic, Ramoz, Haroutunian, Davis, & Buxbaum, 2003; 
$ ƑՊEstimated least squared means for assessed proteins
om|uoѴ 	 NƷņ	
RAP (AIU) 63.6 ± 6.2 30.8 ± 6.3* 16/15
Aβ (ng/ml) 55.9 ± 27.7 152.0 ± 27.6* 15/15
Soluble tau 
(ng/ml)
0.1 ± 0.8 6.6 ± 0.8* 15/14
Insoluble tau 
(ng/ml)
4.8 ± 5.4 31.6 ± 5.2* 15/15
LRP (pg/ml) 954.8 ± 123.3 883.0 ± 123.3 12/15
NeuN (AIU) 319.1 ± 52.7 293.0 ± 51.3 16/17
Note: Group values are expressed as mean ± standard error. *p < .0001 
versus controls. These means were estimated from a model setting age 
to 75 years and postmortem delay to 3 hr.
Abbreviations: AD, Alzheimer's disease; AIU, arbitrary volume intensity 
units; C, control; N, number of cases.
 &! ƑՊBar graphs showing significantly elevated average 
total Aβ (a, p < .0001), soluble tau (b, p < .0001), and insoluble tau 
(c, p < .0001) protein levels in AD brain tissue compared to controls. 
Error bars = standard error
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et al., 2007; Qiu, Strickland, Hyman, & Rebeck, 2001) or decreases 
(Kang et al., 2000) compared to controls. Cellular and regional 
variations (Kanekiyo & Bu, 2014), genetics (Kang et al., 2000), age 
at disease onset, and age at death (Kang et al., 2000) have all been 
proposed to affect LRP1 and may explain some of the previously 
reported variations. However, our findings in the temporal cor-
|;7omo|vrrou|ru;bovv|7b;vvbm]|_;v-l;u;]bomŐ-|vb
et al., 2007) and we did not observe any association between LRP1 
and age at onset (p = .541) or age at death (p = .196). While the 
present study did not specifically analyze changes in secreted 
LRP1, previous studies examining this fraction have also reported 
conflicting results (Causevic et al., 2003; Kang et al., 2000), 
thereby highlighting the complexity in this area and the need for 
additional research.
The relationship between RAP and tau pathology (soluble and 
insoluble tau) is less clear as no previous studies have investigated 
the interaction between these proteins either in vitro or in vivo. 
However, the strong relationship between Aβ and tau (Figure 2) sug-
gests that any relationship with tau may be indirect. This is further 
supported by our observations of a lack of decrease in RAP protein 
expression in tauopathies such as frontotemporal lobar degeneration 
with tau deposition (FTLD-tau vs. control RAP protein p = .144; see 
Figure S1). Interestingly, a combined genetic association between 
tau and LRP1 polymorphisms has previously been associated with a 
sixfold increased risk for AD, possibly via the alteration of intracel-
lular cholesterol levels and tau phosphorylation (Vázquez-Higuera 
et al., 2009), although we did not identify any association between 
LRP1 and tau in the present study. Two previous studies (Sánchez-
Guerra et al., 2001; Vázquez-Higuera et al., 2011) have also failed to 
detect an association between single LRP1 or tau polymorphisms 
and AD, although the observation of reduced neurofibrillary tangle 
burden in statin-treated AD patients postmortem (Li et al., 2007) 
suggests the relationship between tau and cholesterol pathways 
warrants further research.
Neuronal cell loss is a widely accepted feature of the AD brain. 
Its accurate measurement requires knowledge of the degree of atro-
phy, something which is difficult to do using isolated tissue samples 
of similar volumes. Hence, some studies report neuronal cell loss in 
medial temporal and neocortical regions at end-stage AD (Andrade-
ou-;v;| -Ѵĺķ ƑƏƐƒőķ_bѴ;o|_;u v|7b;v u;rou|mo vb]mb=b1-m| 1;ѴѴ
loss, even in early affected hippocampal regions (Furcila, Dominguez-
Alvaro, DeFelipe, & Alonso-Nanclares, 2019), supporting the notion 
that there is great variability in neuronal density in atrophied AD 
|bvv;v Őu;m7|ķ u1hm;uķ ou-vhbķ -];uķ ş ;u|ķ ƑƏƐƔőĺ $_;
findings in the present study were of a nonsignificant trend toward 
reduced NeuN in the same tissue volumes measured from the AD 
group compared to controls. This would be consistent with an overall 
neuronal loss in a region with tissue atrophy in AD.
ƔՊ |Պ&"
Together with the evidence from both in vitro and in vivo animal 
studies, our observation that RAP is reduced in the AD brain and is 
significantly associated with increased Aβ pathology suggests that 
RAP plays an important role in the accumulation and aggregation 
of Aβ in AD, possibly via an LRP1-independent mechanism. Further 
studies are required to elucidate any structural basis for RAP-Aβ 
binding and to further our understanding of this complex cellular 
process.
 &! ƒՊScatter plot depicting the inverse relationship 
between RAP protein levels and total AβŐ-ķ!ƷƴĺƓƑѵķp = .021), 
soluble tau (b, RƷƴĺƔѶƑķp = .001), and insoluble tau (c, RƷƴĺƔѵѵķ
p = .002) in AD brain tissue extracts
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